Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.67 USD
-0.15 (-3.93%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.68 +0.01 (0.27%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
Atea Pharmaceuticals, Inc. (AVIR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.88 | $6.88 | $6.88 | 80.10% |
Price Target
Only one analyst offered a short-term price target of $6.88 for Atea Pharmaceuticals, Inc. This represents an increase of 80.1% from the last closing price of $3.82.
Analyst Price Targets (1 )
Broker Rating
Atea Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, one is Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 0 | 0 |
Sell | 0 | 0 | 0 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 3.00 | 3.00 | 3.00 | 3.23 | 3.23 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/30/2024 | William Blair | Andy T Hsieh | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 3 |
Average Target Price | $6.88 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.50 |
AVIR FAQs
Atea Pharmaceuticals, Inc. (AVIR) currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 3 brokerage firms.
The average price target for Atea Pharmaceuticals, Inc. (AVIR) is $6.88. The current on short-term price targets is based on 2 reports.
The forecasts for Atea Pharmaceuticals, Inc. (AVIR) range from a low of $6.88 to a high of $6.88. The average price target represents a increase of $87.47 from the last closing price of $3.67.
The current UPSIDE for Atea Pharmaceuticals, Inc. (AVIR) is 87.47%
Only one analyst offered a short-term price target of $6.88 for Atea Pharmaceuticals, Inc. This represents an increase of 80.1% from the last closing price of $3.82.